Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms

Detalles Bibliográficos
Autores principales: Yang, Joe, Naik, Jaesh, Massello, Matthew, Ralph, Lewis, Dillon, Ryan James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334491/
https://www.ncbi.nlm.nih.gov/pubmed/35749011
http://dx.doi.org/10.1007/s40121-022-00660-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334491/
https://www.ncbi.nlm.nih.gov/pubmed/35749011
http://dx.doi.org/10.1007/s40121-022-00660-6

Ejemplares similares